profit from every $100 of sales.
$0$100
Kymera Therapeutics
$127.57+0.31% today
+100.5% in 1 year
1-year low $63.631-year high $138.86
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kymera Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $46.8 million in 2022 to $39.2 million in 2025, with -$311 million of profit last year.
SalesProfit
Kymera Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kymera Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kymera Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 34 | 73 | 47 | 79 | 47 | 39 | |
| – | – | 0 | 0 | 0 | 0 | |
| -46 | -101 | -161 | -166 | -257 | -346 | |
| – | – | -152 | -143 | -216 | -303 | |
| -46 | -100 | -155 | -147 | -224 | -311 | |
| -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | |
| – | – | 0.0% | 0.0% | 0.0% | 0.0% | |
| -136.1% | -138.0% | -344.4% | -210.6% | -545.4% | -881.2% | |
| -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 487 | 606 | 603 | 576 | 978 | 1,743 |
| Cash | 31 | 48 | 68 | 110 | 120 | 357 |
| Total debt | – | – | 17 | 85 | 88 | 82 |
| Total liabilities | 203 | 146 | 113 | 181 | 142 | 163 |
| 284 | 460 | 490 | 395 | 836 | 1,580 | |
| 17 | 48 | 54 | 58 | 75 | 84 | |
| – | – | -24.1% | -24.2% | -19.1% | -14.8% | |
| -16.1% | -21.8% | -31.6% | -37.2% | -26.8% | -19.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 88 | -129 | -153 | -103 | -195 | -233 | |
| 9 | 2 | 3 | 34 | 13 | 1 | |
| 79 | -131 | -156 | -137 | -207 | -234 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 5 | 25 | 35 | 43 | 55 | 60 |
Valuation
- –
- –
- –
- 5.4×
- 277.7×
- –
- –
- -2.2%
- -2.9%
- 0.0%
Profitability
- 0.0%
- -881.2%
- -794.0%
- -594.7%
- -22.2%
- -25.0%
- -25.0%
- -18.9%
- -22.4%
- 650.0%
Growth
- +2.9%
- –
- −13.0%
- –
- +15.2%
Financial health
- -0.9×
- 0.05
- 4.8%
- -1,508.9×
- 10.81
- 10.81
- 0.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 952
Bottom 24%of 887
Bottom 28%of 987
What analysts expect
- Average price target
- $118.87
- Range
- $90.00 – $138.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.71 | -0.89 | +20.2% |
| Feb 26, 2026 | -0.97 | -0.78 | −23.8% |
| Nov 4, 2025 | -0.90 | -0.71 | −26.8% |
| Aug 11, 2025 | -0.95 | -0.83 | −14.5% |
| May 9, 2025 | -0.82 | -0.92 | +10.9% |
| Feb 27, 2025 | -0.88 | -0.76 | −15.8% |
| Oct 31, 2024 | -0.82 | -0.83 | +1.2% |
| Aug 7, 2024 | -0.58 | -0.69 | +15.9% |
News
Kymera Therapeutics, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
40No pass
Philip Fisher
22No pass
Peter Lynch
46No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Kymera Therapeutics
Is Kymera Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kymera Therapeutics AI analysis
What does Kymera Therapeutics do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It is in Biotechnology, based in Watertown, MA, United States, with 253 employees.
Does Kymera Therapeutics pay a dividend?
No. Kymera Therapeutics does not pay a dividend at the moment.
Is Kymera Therapeutics stock halal?
Yes. Kymera Therapeutics passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
How has Kymera Therapeutics stock done over the past year?
Up 100.5% over the past twelve months, to $127.57. It traded between $63.63 and $138.86 and is 8.1% below its high.
Who are Kymera Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kymera Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.